FDA Reconsiders Ban on Compounded Versions of Eli Lilly's Weight Loss Drug

The FDA has agreed to review its decision to remove tirzepatide from its shortage list, impacting access to cheaper compounded versions.

The FDA's decision to reconsider follows a lawsuit by the Outsourcing Facilities Association, arguing tirzepatide remains in short supply.
Compounded versions of tirzepatide are more affordable alternatives for patients, especially with limited insurance coverage for weight loss uses.
Eli Lilly has been actively opposing the production of compounded versions, issuing cease-and-desist letters to various sellers.
The FDA's initial removal of tirzepatide from the shortage list was met with significant backlash from pharmacies and patients.
Despite the FDA's claim of resolved shortages, pharmacies report ongoing difficulties in obtaining the branded drug.